Press Releases

Date Title
10/11/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , Oct. 11, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on October 3, 2019 it issued inducement awards to two new
10/02/19
Summary ToggleT2 Biosystems to Showcase Latest Innovations at IDWeek 2019 Printer Friendly Version Company will highlight breakthrough technology that helps rapidly diagnose bloodstream infections for patients suspected of sepsis   LEXINGTON, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical
09/30/19
Summary ToggleT2 Biosystems’ T2Resistance™ Panel is Now Available as a Research Use Only (RUO) Test in the U.S. Printer Friendly Version Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections   LEXINGTON, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for
09/26/19
Summary ToggleT2 Biosystems to Present at the 2019 Cantor Global Healthcare Conference Printer Friendly Version LEXINGTON, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough , chairman and chief executive officer, and John Sprague , chief
09/25/19
Summary ToggleT2 Biosystems Enters into Distribution Agreement to Expand its Innovative Rapid Diagnostic Technologies to Puerto Rico and the U.S. Virgin Islands Printer Friendly Version LEXINGTON, Mass. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into an exclusive distribution agreement that allows the Company to
09/24/19
Summary ToggleT2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio Printer Friendly Version Graduation underscores the critical progress that T2MR® technology has made in the rapid diagnosis of bacterial infections and accelerating time to appropriate treatment   LEXINGTON, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and
09/19/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on September 9, 2019 it issued inducement awards to four
09/11/19
Summary ToggleT2 Biosystems Receives Funding from BARDA to Advance Technology for Diagnosis and Treatment of Bloodstream Infections Printer Friendly Version LEXINGTON, Mass. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it has been awarded a milestone-based contract
09/10/19
Summary ToggleT2 Biosystems to Host Conference Call to Discuss Awarding of Multi-Million Dollar BARDA Contract Printer Friendly Version Contract includes initial phase valued at $6 million, with a total value up to $69 million Call will also cover restructuring of CRG term loan agreement and Breakthrough Technology contract with Premier Inc. Company to host conference call and webcast at 8:30 a.m.
09/10/19
Summary ToggleT2 Biosystems Announces Restructuring of CRG Term Loan Agreement Printer Friendly Version Extends Interest-Only Payment Period Through December 2022 and Reduces Minimum Revenue Targets LEXINGTON, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced